Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CleanSpark Inc (CLSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CleanSpark Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while CleanSpark Inc trades at $11.62 (market cap $3.13B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CLSK | |
|---|---|---|
Market Cap | $5.07B | $3.13B |
Sector | Health | Technology |
52-Week High | $29.45 | $23.20 |
52-Week Low | $20.06 | $8.18 |
Enterprise Value | $4.19B | $4.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
CleanSpark trades at $12.18, up 5.73% today, but faces bearish technical signals with the stock trading near key support levels. The company reported disappointing Q3 2026 results with a $0.89 EPS loss missing estimates, though it secured a significant $6.6 billion AI data center lease that signals strategic expansion beyond Bitcoin mining. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $24.13 price target representing 98% upside potential.
The outlook balances substantial growth potential from the AI infrastructure pivot against near-term execution risks and persistent losses. While the $6.6 billion lease provides long-term revenue visibility, investors face dilution concerns and the challenge of transitioning profitability amid volatile market conditions. The disconnect between bearish technicals and bullish analyst sentiment creates a high-risk, high-reward scenario for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
